MedTrace Logo

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

NCT03706326 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-16

No results posted yet for this study

Summary

The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.

Conditions

  • Advanced Esophageal Cancer

Interventions

BIOLOGICAL

Anti-MUC1 CAR-T cells

Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.

BIOLOGICAL

PD-1 knockout Engineered T cells

Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.

COMBINATION_PRODUCT

CAR-T combined with PD-1 Knockout T cells

Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients

Sponsors & Collaborators

  • Guangzhou Anjie Biomedical Technology Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2021-09-28
Completion
2021-09-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706326 on ClinicalTrials.gov